Thromboembolism - Pipeline Review, H1 2018 Market Report; Launched via MarketResearchReports.com

Thromboembolism - Pipeline Review, H1 2018, provides an overview of the Thromboembolism (Cardiovascular) pipeline landscape.

When a blood clot (thrombus) breaks and travels in the blood, this is called a thromboembolism. Symptoms include warmth, edema, and erythema, and may also include dilated veins (collaterals) on the chest wall or leg. Risk factors include hypertension, diabetes mellitus, cigarette smoking, and high cholesterol levels. Treatment includes anticoagulants, thrombolytic therapy and surgery.

Report Highlights

Thromboembolism - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Thromboembolism (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Thromboembolism (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Thromboembolism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, IND/CTA Filed and Preclinical stages are 3, 4, 1 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.

Thromboembolism (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Thromboembolism (Cardiovascular).
• The pipeline guide reviews pipeline therapeutics for Thromboembolism (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Thromboembolism (Cardiovascular) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Thromboembolism (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Thromboembolism (Cardiovascular)

Reasons to buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Thromboembolism (Cardiovascular).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Thromboembolism (Cardiovascular) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Spanning over 67 pages “Thromboembolism - Pipeline Review, H1 2018” report covers Introduction, Report Coverage, Thromboembolism - Overview, Thromboembolism - Therapeutics Development, Thromboembolism - Therapeutics Assessment, Thromboembolism - Companies Involved in Therapeutics Development, Thromboembolism - Drug Profiles, Thromboembolism - Dormant Projects, Appendix. This report Covered Companies - Bayer AG, China Biologic Products Inc, Daiichi Sankyo Co Ltd, F. Hoffmann-La Roche Ltd, Green Cross Corp, Ionis Pharmaceuticals Inc, Johnson & Johnson, Portola Pharmaceuticals Inc, Verseon Corp.

Please visit this link for more details: http://mrr.cm/UM8

Find all Pharma and Healthcare Reports at: http://www.marketresearchreports.com/pharma-healthcare

Related Reports;

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H1 2018 - Visit at - http://mrr.cm/UMh

P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Pipeline Review, H1 2018 - Visit at - http://mrr.cm/UM7